Simon Parlow, Pietro Di Santo, Lee H Sterling, Laura Goodliffe, Pouya Motazedian, Graeme Prosperi-Porta, Baylie Morgan, Zandra Koopman, Richard G Jung, Melissa Fay Lepage-Ratte, Lisa Robinson, Hannah Feagan, Trevor Simard, George A Wells, Kwadwo Kyeremanteng, Craig Ainsworth, Faizan Amin, Jeffrey A Marbach, Shannon M Fernando, Marino Labinaz, Emilie P Belley-Cote, Benjamin Hibbert, Rebecca Mathew
BACKGROUND: Cardiogenic shock (CS) is a state of end-organ hypoperfusion related to cardiac dysfunction. Current guidelines recommend consideration of inotrope therapy in patients with CS, however no robust data support their use. The purpose of the CAPITAL DOREMI2 trial is to examine the efficacy and safety of inotrope therapy against placebo in the initial resuscitation of patients with CS. METHODS AND DESIGN: This is a multi-center, double-blind, randomized, placebo-controlled trial comparing single-agent inotrope therapy to placebo in patients with CS...
April 22, 2023: American Heart Journal